Endocyte, a subsidiary of Advanced Accelerator Applications, specializes in developing nuclear medicine theragnostic pairings for oncology indications. The company operates in the healthcare and biotechnology sector, focusing on creating advanced radiopharmaceuticals for both diagnostic and therapeutic purposes. Endocyte's core products include radioligand therapies and molecular imaging agents used in Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT). These products are designed to improve the diagnosis and treatment of cancer, offering a more targeted approach to patient care.

Endocyte serves a diverse range of clients, including hospitals, research institutions, and healthcare providers. The company operates primarily in the oncology market, which is a rapidly growing sector due to the increasing prevalence of cancer and the demand for more effective treatments. Endocyte's business model is based on the development, clinical testing, and commercialization of its radiopharmaceutical products. Revenue is generated through the sale of these products, as well as through partnerships and collaborations with other healthcare organizations.

Endocyte's innovative approach to nuclear medicine aims to transform patient outcomes by providing more precise and effective treatment options. The company is committed to advancing the field of oncology through continuous research and development, clinical trials, and regulatory approvals.

Keywords: nuclear medicine, theragnostics, oncology, radiopharmaceuticals, PET, SPECT, radioligand therapy, molecular imaging, clinical trials, healthcare innovation.